Home

Nantahala Capital Management, LLC

CIK 1472322 · last filed 2025-01-30

Nantahala Capital Management, LLC is a corporate insider who has filed 5 SEC Form 4 insider transactions across 2 companies since 2012. The most recent filing shows the insider sold $540 of EVOK on Jan 30, 2025. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. The firm reports its address in New Canaan, CT. 21 SEC filings were submitted jointly with Wilmot B. Harkey.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

5

Lifetime Open-Market Net

-$1.81M

Filer Profile

Reported Address
130 MAIN ST.
2ND FLOOR
NEW CANAAN, CT 06840
Phone
(203) 404-1172
State of Incorporation
MA
Formerly Known As
Nantahala Capital Management, LLC (2009–2026)
Related Filers
Wilmot B. Harkey — 21 joint filings, latest 2026-03-17
Daniel Mack — 21 joint filings, latest 2026-03-17
LUXFER HOLDINGS PLC — 9 joint filings, latest 2024-11-14
Cerecor Inc. — 7 joint filings, latest 2026-08-14
EMMIS CORP — 4 joint filings, latest 2020-02-13
Fortress Biotech, Inc. — 4 joint filings, latest 2024-02-14
RMR GROUP INC. — 4 joint filings, latest 2025-08-14
GAIAM, INC — 3 joint filings, latest 2025-05-15
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Evoke Pharma Inc (EVOK) Delisted 10%+ Owner 148,153 $11.00 $1.63M -$540 1 2025-01-30
Sucampo Pharmaceuticals, Inc. (SCMP) Delisted 10%+ Owner 275,640 — — -$1.81M 1 2012-04-24

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-01-30 Evoke Pharma Inc (EVOK) Delisted Sell (S) −123 -$540 EDGAR
2022-07-15 — Other (J) — $0
2022-07-15 — Other (J) — $0
2020-11-16 — Mixed — $0
2012-04-24 Sucampo Pharmaceuticals, Inc. (SCMP) Delisted Sell (S) −219,900 -$1.81M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.